Novartis submits application to the FDA for meningitis B vaccine candidate Bexsero(R) to help protect US adolescents and young adults

Submission follows receipt of Breakthrough Therapy designation in April 2014, highlighting unmet need for a licensed vaccine for serogroup B in the US[1] Meningitis B is a rare but aggressive disease that can kill or cause serious life-long disability within 24 hours of onset, often with initial flu-like symptoms[2],[3],[4] Bexsero, approved in 34 countries, was recently provided to two US …